Neovascular Age-Related Macular Degeneration in the Very Old (≥90 Years): Epidemiology, Adherence to Treatment, and Comparison of Efficacy

Table 3

Two-year results on Aflibercept treatment for neovascular age-related macular degeneration in patients aged ≥90 years.

	Aflibercept ()
	Mean (95% CI)	P value
ΔBCVA, ETDRS letters
4 months	5.5 (1.1 to 9.9)	0.014
12 months	3.9 (−0.9 to 8.8)	0.106
24 months	3.4 (−3.4 to 10.2)	0.320
Δ average CRT, μm
4 months	−148 (−185 to −111)	<0.001
12 months	−142 (−181 to −104)	<0.001
24 months	−141 (−185 to −97)	<0.001

BCVA: best-corrected visual acuity; CRT: central retinal thickness; CI: confidence interval. values were calculated using the one sample t-test with test value = 0.